Lexicon Pharmaceuticals (LXRX) CFO Coiante acquired 160,237 shares
Insider transactions reported
Scott M Coiante (SVP, Chief Financial Officer at Lexicon Pharmaceuticals Inc., LXRX) reported that they acquired 160,237 shares, and gave up 54,881 shares at $1.47 to cover taxes or an exercise price on Feb 28, 2026. After these transactions the filing shows 105,356 shares held directly.
- Reporting person
- Coiante Scott M
- Role
- SVP, Chief Financial Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 28, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +160,237 | - | - | 160,237 direct |
| Feb 28, 2026 | Shares withheld for taxes or exercise price (F) | Common Stock2 | -54,881 | $1.47 | $80.7K | 105,356 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 28, 2026 | Exercise or conversion of a derivative (M) | Restricted Stock UnitsOn 160,237 Common Stock1, 3 | -160,237 | - | - | 320,473 direct |
Holdings before and after
- Common Stock: 0 to 105,356 direct
- Restricted Stock Units: 480,710 to 320,473 direct
Footnotes from the filing
- 1. Each restricted stock unit represents a contingent right to receive one share of common stock.
- 2. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
- 3. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Transaction codes in this filing
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Coiante report in this LXRX Form 4?
Scott M Coiante (SVP, Chief Financial Officer at Lexicon Pharmaceuticals Inc., LXRX) reported that they acquired 160,237 shares, and gave up 54,881 shares at $1.47 to cover taxes or an exercise price on Feb 28, 2026. After these transactions the filing shows 105,356 shares held directly.
How many LXRX shares does Coiante hold after this filing?
The filing shows 105,356 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code M mean on an SEC Form 4?
Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
Historical context for LXRX
Across the 16 sessions after earlier LXRX headlines, the stock closed higher 8 times and lower 7 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LXRX | SPY |
|---|---|---|---|
| Feb 26, 2026 | Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 | +0.0% | -0.6% |
| Feb 9, 2026 | Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement | -2.4% | +0.5% |
| Jan 30, 2026 | Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placementand 1 other headline that session | -19.4% | -0.3% |
| Jan 23, 2026 | Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary | -3.4% | +0.0% |
| Jan 21, 2026 | Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain | +19.1% | +1.2% |
| Jan 12, 2026 | Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference | +0.9% | +0.2% |
Earlier insider filings at LXRX
- Mar 3, 2026Chief Executive Officer Exton Michael covered exercise/tax liability with 204,831 shares and converted options into 503,263 shares (SEC Form 4)
- Feb 27, 2026Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)
- Feb 25, 2026Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)
- Feb 23, 2026Director Debbane Raymond bought $219,755 worth of shares (150,000 units at $1.47), increasing direct ownership by 9% to 1,804,186 units (SEC Form 4)
- Feb 19, 2026Director Artal Participations S.A R.L. was granted 41,290 units of Series B Convertible Preferred Stock (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow LXRX and get a push notification the moment its next story breaks.